Marc Hoffmann

Assistant Professor

University of Kansas Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marc Hoffmann is an Assistant Professor at the University of Kansas Cancer Center in the United States. His research focuses on hematologic malignancies, including the role of Bruton’s Tyrosine Kinase inhibitors and CAR-T cell therapy in chronic lymphocytic leukemia and follicular lymphoma. He actively investigates treatment options such as selective Bcl-2 inhibitors and the safety of novel therapies for patients with B-cell malignancies. His recent publications emphasize both patient perspectives and clinical efficacy in cancer treatment.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (2)

Christopher Jensen

University of North Carolina

UNITED STATES

View details

Deborah Stephens

Assistant Professor

Huntsman Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marc Hoffmann

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Rare presentation and unconventional treatment of Rosai–Dorfman disease

Routine consolidation of early stage primary bone lymphoma with radiation therapy does not improve outcomes

Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias

Apoptotic colopathy following bendamustine therapy

Collaborators (2)

Christopher Jensen

Deborah Stephens

Make your next move.